Compare Pharmarise Holdings Corp. with Similar Stocks
Dashboard
1
The company is Net-Debt Free
- Poor long term growth as Net Sales has grown by an annual rate of 5.50% over the last 5 years
- The company is Net-Debt Free
2
Poor long term growth as Net Sales has grown by an annual rate of 5.50% over the last 5 years
3
The company has declared Negative results for the last 5 consecutive quarters
4
Risky -
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 6,344 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
1.86
-0.05%
0.95
Revenue and Profits:
Net Sales:
16,954 Million
(Quarterly Results - Feb 2026)
Net Profit:
-125 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
1.16%
0%
1.16%
6 Months
-1.13%
0%
-1.13%
1 Year
7.58%
0%
7.58%
2 Years
-19.97%
0%
-19.97%
3 Years
-17.97%
0%
-17.97%
4 Years
-26.26%
0%
-26.26%
5 Years
-32.52%
0%
-32.52%
Pharmarise Holdings Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.50%
EBIT Growth (5y)
-10.23%
EBIT to Interest (avg)
16.35
Debt to EBITDA (avg)
2.65
Net Debt to Equity (avg)
1.30
Sales to Capital Employed (avg)
3.11
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.02%
ROE (avg)
5.75%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.91
EV to EBIT
27.07
EV to EBITDA
7.47
EV to Capital Employed
0.97
EV to Sales
0.24
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
3.57%
ROE (Latest)
-0.68%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Sideways
Sideways
Moving Averages
Bullish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Feb'26 - QoQ
Feb'26
Nov'25
Change(%)
Net Sales
16,954.00
16,849.00
0.62%
Operating Profit (PBDIT) excl Other Income
591.00
636.00
-7.08%
Interest
69.00
62.00
11.29%
Exceptional Items
-20.00
45.00
-144.44%
Consolidate Net Profit
-125.00
128.00
-197.66%
Operating Profit Margin (Excl OI)
12.20%
14.60%
-0.24%
USD in Million.
Net Sales
QoQ Growth in quarter ended Feb 2026 is 0.62% vs 0.57% in Nov 2025
Consolidated Net Profit
QoQ Growth in quarter ended Feb 2026 is -197.66% vs 681.82% in Nov 2025
Annual Results Snapshot (Consolidated) - May'25
May'25
May'24
Change(%)
Net Sales
63,508.00
54,466.00
16.60%
Operating Profit (PBDIT) excl Other Income
1,788.00
2,086.00
-14.29%
Interest
178.00
66.00
169.70%
Exceptional Items
-129.00
-703.00
81.65%
Consolidate Net Profit
-381.00
-342.00
-11.40%
Operating Profit Margin (Excl OI)
4.60%
16.80%
-1.22%
USD in Million.
Net Sales
YoY Growth in year ended May 2025 is 16.60% vs 4.68% in May 2024
Consolidated Net Profit
YoY Growth in year ended May 2025 is -11.40% vs -198.56% in May 2024
About Pharmarise Holdings Corp. 
Pharmarise Holdings Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






